LL-37 is the only human cathelicidin antimicrobial peptide — a 37-amino-acid peptide cleaved from the precursor protein hCAP-18. It serves dual roles: direct antimicrobial activity against bacteria, viruses, and fungi, and immune modulation through chemokine signaling and immune cell recruitment. This protocol covers its application in chronic infection support, biofilm-associated conditions, and immune defense optimization.

Mechanism overview

LL-37 operates through multiple mechanisms that distinguish it from conventional antimicrobials:

Direct antimicrobial action: LL-37 inserts into bacterial cell membranes, disrupting their integrity and causing lysis. This membrane-targeting mechanism makes resistance development difficult — bacteria would need to fundamentally alter their membrane structure to evade LL-37.

Biofilm disruption: LL-37 penetrates and disrupts bacterial biofilms — the protective polysaccharide matrices that shield chronic bacterial colonies from antibiotics and immune surveillance. This is particularly relevant for MARCoNS (Multiple Antibiotic Resistant Coagulase-Negative Staphylococci), chronic sinusitis biofilms, and other biofilm-associated infections.

Immune modulation: LL-37 recruits immune cells (neutrophils, monocytes, T-cells) to infection sites through chemotactic signaling. It also modulates dendritic cell activation, influences Th1/Th2 balance, and promotes wound healing through angiogenesis and keratinocyte migration.

Endotoxin neutralization: LL-37 binds and neutralizes lipopolysaccharide (LPS), reducing the inflammatory cascade triggered by gram-negative bacterial components.

Dose selection

Standard dose: 100 mcg subcutaneous daily

Conservative start: 50 mcg subcutaneous daily for the first week

Moderate dose: 100 mcg subcutaneous daily (most common clinical dose)

Aggressive dose: 200 mcg subcutaneous daily (for severe biofilm-associated conditions, under practitioner supervision)

Dose selection rationale: LL-37's dual antimicrobial and immunomodulatory effects are dose-dependent. The 100 mcg dose provides adequate antimicrobial signaling while maintaining the immune-modulatory balance. Higher doses increase antimicrobial potency but may increase the risk of pro-inflammatory effects — LL-37 at supraphysiological concentrations can shift from immunomodulatory to pro-inflammatory.

Start conservatively. LL-37 can trigger Herxheimer-like reactions (die-off reactions) if significant biofilm disruption releases bacterial antigens rapidly. Starting at 50 mcg and titrating up over 7-10 days reduces this risk.

Route and administration

Primary route: Subcutaneous injection

Injection site: Abdominal subcutaneous, rotating sites. For localized infections (chronic sinusitis), intranasal delivery at reduced doses (25-50 mcg) has been used by some practitioners, though intranasal bioavailability data for LL-37 is limited.

Reconstitution: Reconstitute lyophilized LL-37 with bacteriostatic water. Typical reconstitution: 1 mL bacteriostatic water to a 5 mg vial = 5 mg/mL (5000 mcg/mL). A 100 mcg dose = 0.02 mL. Use insulin syringes with 0.01 mL graduations for accurate dosing at these small volumes.

Storage: Refrigerate reconstituted solution. LL-37 is reasonably stable in solution but should be used within 3-4 weeks after reconstitution. Do not freeze reconstituted solution.

Timing: Morning administration preferred. No strict meal timing requirements.

Cycle structure

Acute infection support

Duration: 2-4 weeks

Dose: 100-200 mcg SC daily

Context: Active infection where conventional antibiotics have been insufficient, particularly if biofilm involvement is suspected

Chronic biofilm-associated conditions (MARCoNS, chronic sinusitis)

Phase 1 (weeks 1-2): 50-100 mcg SC daily — titration and assessment

Phase 2 (weeks 3-6): 100-200 mcg SC daily — active biofilm disruption

Phase 3 (weeks 7-8): 100 mcg SC every other day — consolidation

Total duration: 6-8 weeks

Repeat cycle after 4-week rest if cultures remain positive

Immune defense maintenance

Duration: 4-6 week cycles, 2-3 times per year

Dose: 100 mcg SC, 3-5 times per week

Context: Seasonal immune support, recurrent infection prevention

CIRS protocol integration

Position in protocol: LL-37 is typically used after binder therapy and before or concurrent with VIP therapy in the Shoemaker CIRS protocol sequence.

Duration: 4-8 weeks, coordinated with MARCoNS treatment

Dose: 100 mcg SC daily

Combination strategy

LL-37 + Thymosin Alpha-1 (antimicrobial + immune reconstitution)

Rationale: LL-37 directly attacks pathogens and biofilms. Thymosin alpha-1 restores adaptive immune competence — improving T-cell maturation, NK cell function, and dendritic cell antigen presentation. The combination addresses both the microbial burden (LL-37) and the immune system's capacity to maintain clearance (Tα1).

LL-37: 100 mcg SC daily
Thymosin alpha-1: 1.6 mg SC 2-3x/week
Duration: 6-8 weeks
Best for: chronic infections with documented immune suppression, post-viral immune dysregulation with secondary infections

LL-37 + KPV (antimicrobial + anti-inflammatory)

Rationale: LL-37's antimicrobial action can trigger inflammatory cascades as biofilms are disrupted and bacterial antigens are released. KPV (Lys-Pro-Val), an alpha-MSH fragment, suppresses NF-kB-mediated inflammation. The combination provides antimicrobial action with inflammatory buffering.

LL-37: 100 mcg SC daily
KPV: 250 mcg SC daily (or oral for GI-specific inflammation)
Duration: 4-6 weeks
Best for: chronic infections with significant inflammatory component, GI infections with mucosal inflammation

LL-37 + BPC-157 (antimicrobial + tissue repair)

Rationale: For chronic infections that have caused tissue damage (chronic gastritis, mucosal erosion, wound infections), LL-37 addresses the microbial component while BPC-157 supports tissue repair through growth factor upregulation and angiogenesis.

LL-37: 100 mcg SC daily
BPC-157: 250-500 mcg SC daily or oral (for GI applications)
Duration: 4-8 weeks

Monitoring and bloodwork

Baseline panel

Complete blood count with differential (neutrophil, lymphocyte counts)
CRP, ESR (inflammatory markers)
Immunoglobulin levels (IgG, IgA, IgM)
MARCoNS nasal culture (if CIRS or chronic sinusitis context)
Site-specific cultures if targeting a known infection
Vitamin D level (25-OH-D) — LL-37 expression is vitamin D-dependent; levels below 40 ng/mL should be corrected

Follow-up (week 4 and post-cycle)

Repeat cultures: MARCoNS clearance, site-specific pathogen reduction
Inflammatory markers: CRP, ESR trending down indicates reduced microbial burden
CBC: normalization of infection-related leukocytosis or lymphopenia
Symptom tracking: infection-related symptoms (congestion, fatigue, wound healing)

Critical monitoring point — Vitamin D optimization

Endogenous LL-37 production is regulated by vitamin D receptor activation. Supplementing exogenous LL-37 while vitamin D is deficient is pharmacologically suboptimal — the body's own LL-37 production remains suppressed. Optimize vitamin D to 50-70 ng/mL with D3 supplementation (5,000-10,000 IU daily with K2) before or concurrent with the LL-37 protocol.

Side effects and management

Herxheimer-like reactions (die-off): The most significant clinical concern. Biofilm disruption releases bacterial antigens, triggering an acute inflammatory response — fever, malaise, myalgia, headache, worsening of infection-site symptoms. Management: start at 50 mcg, titrate slowly, support detoxification (binders, hydration, electrolytes). If severe, reduce dose or hold for 2-3 days before resuming at a lower dose.
Injection site reactions: Mild erythema and discomfort are common. LL-37 has mild pro-inflammatory properties at the injection site. Rotate sites. Ice application post-injection may reduce discomfort.
Transient inflammatory flare: LL-37 activates immune cell recruitment. Some individuals experience a brief increase in localized inflammation (sinusitis worsening, skin inflammation) as immune cells are mobilized to infection sites. This typically resolves within 3-5 days and is a sign of immune engagement rather than treatment failure.
GI effects: Uncommon with subcutaneous administration. If using intranasal delivery, post-nasal drip of LL-37 may cause mild throat irritation.

Contraindications

Active autoimmune disease in flare: LL-37's immune-activating properties may exacerbate autoimmune inflammation. Use during quiescent periods only, and with practitioner supervision.
Psoriasis: LL-37 has been implicated in psoriasis pathogenesis — it can form complexes with self-DNA that activate plasmacytoid dendritic cells and drive psoriatic inflammation. Avoid in active psoriasis. Use with extreme caution in psoriasis-prone individuals.
Pregnancy and lactation: No safety data. Avoid.
Severe immunosuppression (transplant recipients): LL-37's immune-activating effects may interfere with immunosuppressive regimens. Contraindicated without transplant specialist involvement.
History of rosacea: LL-37 has been identified as a contributing factor in rosacea pathogenesis through activation of kallikrein-5 protease pathways. Individuals with active or history of rosacea should use LL-37 with caution and monitor for facial flushing or skin changes.
Concurrent antibiotic therapy: LL-37 can be used alongside conventional antibiotics for synergistic antimicrobial action. However, the Herxheimer reaction risk increases when combining biofilm-disrupting agents. Start LL-37 after the antibiotic course is established rather than introducing both simultaneously.

Reconstitution notes

Peptide handling: LL-37 is a relatively long peptide (37 amino acids) with amphipathic properties — it has both hydrophilic and hydrophobic domains. This makes it susceptible to surface adsorption on glass and plastic. Use low-binding syringe tips when possible, and avoid storing reconstituted solution in glass vials for extended periods if alternative containers are available.

Concentration accuracy at low doses: The 100 mcg dose represents a very small volume (0.02 mL at 5 mg/mL concentration). Some practitioners reconstitute at lower concentrations (1 mL per 1 mg vial = 1 mg/mL) to increase injection volume and improve dosing accuracy. The tradeoff is faster degradation in the more dilute solution — use within 2 weeks at this concentration.

Do not combine in the same syringe: If administering LL-37 alongside other peptides (KPV, Tα1), draw and inject separately. LL-37's membrane-active properties may interact with other peptides in solution, potentially altering their structure or activity.

Troubleshooting

MARCoNS culture remains positive after 6 weeks: Ensure concurrent biofilm-disruption support (EDTA nasal spray, xylitol rinses). Consider increasing LL-37 dose to 200 mcg if tolerated. Verify vitamin D optimization. Some biofilm-producing strains require 2-3 cycles with adequate rest periods for full clearance.
Herxheimer reactions too severe to continue: Reduce LL-37 to 25-50 mcg every other day. Add KPV 250 mcg daily for NF-kB suppression. Increase binder support (activated charcoal, cholestyramine, bentonite clay). Ensure adequate hydration (2-3 L/day). Resume dose escalation only when symptoms stabilize.
No clinical improvement by week 4: Re-culture to verify the target organism. Ensure the infection is accessible to systemic LL-37 (deep tissue infections or sequestered abscesses may not respond to subcutaneous peptide delivery). Consider whether the presentation is truly infectious or whether chronic inflammation without active infection is the primary pathology — in which case, VIP or KPV may be more appropriate than LL-37.
Worsening of skin conditions: LL-37 can be pro-inflammatory in certain skin contexts. Discontinue if new skin lesions appear or existing conditions worsen. Dermatological evaluation recommended.
Night sweats: Some individuals report night sweats during the first 1-2 weeks, likely reflecting immune activation and cytokine release. If manageable, this is a sign of immune engagement. If disruptive, reduce dose temporarily.
Persistent low-grade fever: LL-37 activates innate immune responses that can produce mild systemic inflammation. Temperature elevations of 0.5-1.0 degrees F are not uncommon during the first week. If fever exceeds 100.4 degrees F or persists beyond 5 days, reduce dose and evaluate for concurrent infection being unmasked by immune activation.